Abstract
T regulatory cells (Tregs) are subsets of T lymphocytes specialized in modulating antigen-specific immune responses in vivo. Hence, Tregs represent an ideal therapeutic tool to control detrimental immune reactions. Based on solid pre-clinical results, investigators started testing the safety and efficacy of Treg-based therapies in humans. Despite promising results, a number of issues remain to be solved. We will discuss the results obtained from clinical trials and the challenges and risks we are facing in the further development of Treg-based therapies.
Original language | English |
---|---|
Article number | 593 |
Journal | Frontiers in Immunology |
Volume | 6 |
Issue number | NOV |
DOIs | |
Publication status | Published - 2015 |
Keywords
- FOXP3
- Gene transfer
- IL-10
- T regulatory cells
- T regulatory type 1 cells
- Tolerance
- Treg-based therapy
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy